Free Float 42,87 %
Shares Float 6,75 M
Shares Outstanding 15,76 M
ACTICOR BIOTECH EO 1
Share · FR0014005OJ5 · A3C6GM (XPAR)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ACTICOR BIOTECH EO 1
No Price
Share Float & Liquidity
Company Profile for ACTICOR BIOTECH EO 1 Share
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Company Data
Name ACTICOR BIOTECH EO 1
Company Acticor Biotech SAS
Website
https://acticor-biotech.com
Primary Exchange 
Frankfurt
Frankfurt
WKN A3C6GM
ISIN FR0014005OJ5
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Gilles Avenard
Country France
Currency EUR
Employees 0,0 T
Address Bâtiment Inserm U1148, 75877 Paris
IPO Date 2021-11-01
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | 7V7.F |
| Paris | ALACT.PA |
More Shares
Investors who hold ACTICOR BIOTECH EO 1 also have the following shares in their portfolio:
